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ABSTRACT Zika virus (ZIKV), a mosquito-borne flavivirus discovered in 1947, has
only recently caused large outbreaks and emerged as a significant human pathogen.
In 2015, ZIKV was detected in Brazil, and the resulting epidemic has spread through-
out the Western Hemisphere. Severe complications from ZIKV infection include neu-
rological disorders such as Guillain-Barré syndrome in adults and a variety of fetal
abnormalities, including microcephaly, blindness, placental insufficiency, and fetal
demise. There is an urgent need for tools and reagents to study the pathogenesis of
epidemic ZIKV and for testing vaccines and antivirals. Using a reverse genetics plat-
form, we generated six ZIKV infectious clones and derivative viruses representing di-
verse temporal and geographic origins. These include three versions of MR766, the
prototype 1947 strain (with and without a glycosylation site in the envelope pro-
tein), and H/PF/2013, a 2013 human isolate from French Polynesia representative of
the virus introduced to Brazil. In the course of synthesizing a clone of a circulating
Brazilian strain, phylogenetic studies identified two distinct ZIKV clades in Brazil. We
reconstructed viable clones of strains SPH2015 and BeH819015, representing ances-
tral members of each clade. We assessed recombinant virus replication, binding to
monoclonal antibodies, and virulence in mice. This panel of molecular clones and re-
combinant virus isolates will enable targeted studies of viral determinants of patho-
genesis, adaptation, and evolution, as well as the rational attenuation of contempo-
rary outbreak strains to facilitate the design of vaccines and therapeutics.
IMPORTANCE Viral emergence is a poorly understood process as evidenced by the
sudden emergence of Zika virus in Latin America and the Caribbean. Malleable re-
agents that both predate and span an expanding epidemic are key to understand-
ing the virologic determinants that regulate pathogenesis and transmission. We have
generated representative cDNA molecular clones and recombinant viruses that span
the known ZIKV family tree, including early Brazilian isolates. Recombinant viruses
replicated efficiently in cell culture and were pathogenic in immunodeficient mice,
providing a genetic platform for rational vaccine and therapeutic design.
Zika virus (ZIKV), a member of the Flavivirus genus and closely related to denguevirus (DENV), was first discovered in 1947 in Uganda (1) and until recently had been
responsible for only sporadic human infections in Africa and Asia (2). In the past decade,
however, ZIKV has emerged into new areas, including a large outbreak in Micronesia in
2007, where it is estimated that 73% of the population was infected within a 4-month
period (3), followed by a 2013-2014 outbreak in French Polynesia and subsequent
spread throughout Oceania (4). The ZIKV outbreak in the South Pacific is thought to be
the source of virus introduced to Brazil, supported by the close genetic relationship of
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South Pacific and epidemic Latin American strains (5). The first ZIKV cases in Brazil were
reported in early 2015, with the outbreak initially concentrated in the northeastern
region of the country (6, 7). Although early case reports were consistent with the
self-limited febrile illness observed in previous outbreaks, a surge in cases of micro-
cephaly was reported in the northeastern region of Brazil in the fall of 2015 (8).
Thereafter, a growing body of molecular, immunologic, and epidemiological evidence
has demonstrated a causal role for ZIKV infection in microcephaly as well as a spectrum
of other neurodevelopmental defects, now collectively referred to as “congenital Zika
syndrome” (9). To date, it is unknown why transplacental transmission and teratoge-
nicity have been observed during the current ZIKV epidemic in Latin America but not
in previous outbreaks. Furthermore, this epidemic has revealed a role for sexual
transmission in the spread of ZIKV, a transmission mode not reported for other
flaviviruses (10). While some have speculated that genetic changes in the virus could be
responsible for new pathogenic phenotypes, testing this hypothesis would be aided by
a tractable reverse genetics system to generate panels of isogenic mutants of proposed
viral determinants of pathogenesis.
Although cDNA-based infectious clones (ICs) have been generated for other flavi-
viruses, including West Nile virus, yellow fever virus, DENV, and ZIKV (11–17), flavivirus
reverse genetics systems can be more challenging than those for many other viruses,
because of sequence instability in bacterial vectors (18). Recent efforts to generate ZIKV
recombinant viruses have resulted in different cloning strategies, all of different ZIKV
strains, that have used DNA plasmids with introns or as multipiece systems designed to
overcome these fundamental stability issues (15–17, 19).
Here, we have developed a panel of ZIKV infectious clones, patterned after DENV
and coronavirus strategies (20–22). The ZIKV panel includes three allelic variants of a
historical African strain (MR766) as well as contemporary outbreak strains from French
Polynesia (H/PF/2013) and early epidemic Brazilian strains (SPH2015 and BeH819015),
enabling experimental testing of viral determinants that distinguish the current ZIKV
epidemic from earlier outbreaks. In the process of generating clones of the two
Brazilian strains, we identified sequence abnormalities that impacted virus viability.
Phylogenetic analysis of currently available full-length genomes suggests that two
clades of ZIKV are circulating in Brazil (5). We generated molecular clones and recov-
ered recombinant viruses representing early isolates from both Brazilian ZIKV clades.
Based on our previous experience with DENV infectious clones (20–22), we were
able to partition toxic regions of the ZIKV genome into stable plasmid subclones.
Furthermore, we used nonpalindromic restriction endonuclease sites naturally occur-
ring in the ZIKV genome, allowing directional ligation of digested subgenomic frag-
ments into full-length cDNAs from which full-length infectious transcripts can be
synthesized in vitro. The resulting ZIKV recombinant viruses grow to similar peak titers
as their parental isolate viruses and are recognized by cross-reactive DENV monoclonal
antibodies (MAbs) but not DENV serotype-specific MAbs. Recombinant viruses were
virulent in Ifnar1/  Ifngr1/ C57BL/6J mice, though slightly attenuated compared
to natural isolate viruses. Interestingly, there was a large difference in murine patho-
genesis between the two Brazilian recombinant viruses, driven by one or more of
6 amino acid differences that distinguish the two strains. This highly tractable genetic
platform will be useful for evaluating viral determinants of ZIKV pathogenesis and for
the development and testing of interventions to combat ZIKV disease.
RESULTS
Complete genomic sequence determination of multiple ZIKV strains. Construct-
ing an infectious clone requires knowledge of the complete viral genome sequence.
However, many early ZIKV sequences deposited in GenBank annotated as being a “com-
plete genome” were actually incomplete (accession numbers KU729218, KU707826,
KF383116, etc.), consisting of a complete open reading frame sequence with incom-
plete sequences of the 5= and/or 3= untranslated regions (UTRs). We therefore sought
to determine whether our laboratory stocks of MR766 and H/PF/2013 matched the
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published sequences. MR766 is the prototype ZIKV strain, isolated in Uganda in 1947
(1), and has undergone extensive in vivo and in vitro passaging resulting in substrains.
Conversely, H/PF/2013 is a human clinical isolate from French Polynesia, 2013, with
limited passage in Vero cells (23). Our laboratory stocks of both of these viruses were
grown in C6/36 cells, and cDNA was prepared from infected cell supernatant. Sanger
sequencing was performed on PCR products to obtain a consensus sequence of the
open reading frame, and these exactly matched deposited sequences for each virus
(MR766, accession no. KU955594, and H/PF/2013, accession no. KJ776791). Of interest,
we identified our MR766 strain as being among those substrains that carry a four-codon
deletion that ablates a canonical N-linked glycosylation site in the envelope (E) glyco-
protein (Fig. 1B), rather than an alternative MR766 substrain (and other ZIKV strains)
that encodes a glycosylation site at this position (N154).
We next obtained complete sequences of the 5= and 3= genomic termini for both
strains. We used a modified 5=-3= rapid amplification of cDNA ends (RACE) method
because conventional RACE protocols are dependent upon a 3= poly(A) tail which is
not present on flavivirus genomes (see Fig. S1A in the supplemental material). The
deposited genomic sequence of MR766 included complete 5= and 3= termini, and our
sequences matched these exactly (Fig. S1B and C). As the deposited sequence of
H/PF/2013 consisted of a complete open reading frame with only partial UTR se-
quences, our analysis added 60 nucleotides (nt) to the 5= end and 130 nucleotides to
the 3= end to generate a new complete genomic sequence for this virus (Fig. S1B and
C). An additional contemporary outbreak strain, PRVABC59, a human clinical isolate
from Puerto Rico, 2015, had the same 5= and 3= UTR sequences as H/PF/2013 except for
a single difference in the 3= UTR at nucleotide 10391 (Fig. S1B and C). Interestingly, the
nucleotide change at position 10391 also occurs in both of the early Brazilian ZIKV
isolates (SPH2015 and BeH819015) and matches the PRVABC59 sequence as well. This
represents a diversity of only 0.23% between the 3= UTRs of H/PF/2013 and PRVABC59,
whereas the H/PF/2013 and MR766 3= UTRs differ by 17 nucleotides (3.90%). These
results indicate a high degree of conservation of the 5= and 3= UTR genomic regions,
especially in natural clinical isolates that have not undergone extensive in vitro and in
vivo passages.
Development of a ZIKV reverse genetics system using unidirectional assembly
of a quadripartite genome. We previously developed reverse genetics platforms that
are comprised of multipartite genomes with unidirectional assembly to generate stable
infectious clones for coronaviruses (24, 25) and DENV (20–22). Given the high genetic
relatedness between DENV and ZIKV, we adapted this strategy to design a clone of our
MR766 ZIKV substrain, which lacks E glycosylation due to a 4-amino-acid (aa) deletion
(Gly MR766), using a quadripartite subgenomic system to disrupt toxic genomic
regions by partitioning them onto four high-copy-number plasmids for bacterial am-
plification (Fig. 1A and B). The partition sites were chosen to mimic those used to
construct DENV infectious clones by this method (20) and by the location of naturally
occurring class IIG restriction sites which cleave outside their recognition site, gener-
ating nonpalindromic ends that allow for unidirectional ligation of the purified four
genomic fragments into full-length genomes. A T7 RNA polymerase promoter site was
oriented directly upstream of the first ZIKV nucleotide and used for in vitro transcription
of full-length ligated genomes, while a hepatitis delta virus ribozyme immediately
following the last ZIKV nucleotide generates an authentic 3= terminus on the full-length
infectious genomic RNA (Fig. 1A). These transcripts were electroporated into C6/36
Aedes albopictus cells, which released high-titer infectious virus (approximately 106 to
107 focus-forming units [FFU]/ml) in the culture supernatants (Fig. 1D). These were
collected and passaged once or twice on C6/36 cells to generate virus stocks used for
experiments. To verify the presence of molecularly cloned viruses, we sequenced the
full viral genome, confirming the genetic origins of each recombinant virus. Since the
MR766 infectious clone included engineered ablation of duplicate restriction sites, we
also digested cDNA from the clone and isolate viruses, confirming the expected
restriction fragment sizes from two of the clones (Fig. 1E).
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FIG 1 (A) Schematic diagram of ZIKV MR766 infectious clone. The genome of the virus is divided into 4 fragments using the diagrammed
restriction endonucleases and cloned into high-copy-number vectors. A T7 promoter is placed before the first nucleotide of the ZIKV genome,
and a hepatitis delta virus ribozyme is placed after the final genomic nucleotide for RNA stability. Four restriction endonuclease sites shown
beneath the genome (two PflMI, one SmaI, and one BstAPI) were removed using synonymous changes. Sizes of each fragment are shown, and
the larger size is listed along with the location of the N154 allelic mutations (green star). (B) Amino acid sequences of the 3 allelic MR766 variants
in the region of the N154 glycosylation site on E. Numbers (440 and 460) correspond to amino acid positions in the complete ZIKV genome. (C)
Virus focus images on Vero-81 cells. (D) Growth curves of MR766 isolate and 3 infectious clones done at 37°C. MR766 gly IC had significantly
higher early growth than the other 3 strains by 2-way analysis of variance with Tukey’s test. (E) After reverse transcriptase-PCR, viral amplicons
were subjected to SmaI digestion; only the DNA from the natural isolate was cut. (F) Western blot of E protein from MR766 isolate and 3 infectious
clones performed using the pan-flavivirus MAb 4G2. Size differences of the E protein are shown based on their sequence and glycosylation status.
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Although our substrain of MR766 exactly matched deposited sequences of this virus
(accession number KU955594), other deposited MR766 substrain sequences differ and
encode an intact N-linked glycosylation site at N154 of E. Since this N154 glycosylation
site is a known determinant of virulence, neuroinvasion, and vector competence for
other flaviviruses (26, 27), we constructed an additional MR766 variant with an intact
glycosylation site based on this published sequence (accession number KU720415). A
third clone restoring the 4-aa deletions but not encoding the N-linked glycosylation site
was also generated (accession number LC002520). An amino acid alignment of the
region surrounding the N154 glycosylation site highlights the differences in the clone
viruses (Fig. 1B). Restoration of the 4-aa deletion and functional glycosylation was
confirmed by Western blot analysis of E protein. As expected, glycosylated E migrates
at the highest molecular weight followed by the Del and Gly clones and natural
isolate (Fig. 1F). While peak infectious titers of all three clone viruses reached similar
levels as our isolate virus with the 4-aa deletion (Fig. 1D), the viral clone with restored
glycosylation appears to have an early growth advantage and to make larger infectious
foci than the other allelic mutants (Fig. 1C; Fig. S2).
Utilizing similar strategies, we constructed an infectious clone system for ZIKV strain
H/PF/2013, considered to be a near-predecessor of the current outbreak in the Amer-
icas. Because of the genetic heterogeneity between MR766 and H/PF/2013, different
restriction endonuclease sites were used in clone design (Fig. 2A). After electroporation
of C6/36 cells, titers reached 106 to 107 FFU/ml, equivalent to that of the natural isolate
(Fig. 2B), but the cells demonstrated slightly smaller infectious focus size and morphol-
ogy (Fig. 2C; Fig. S2). We performed multistep growth curves on Vero-81 cells at two
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FIG 2 (A) Schematic diagram of ZIKV H/PF/2013 infectious clone. The genome of the virus is divided into 4 fragments using diagrammed restriction
endonucleases and cloned into high-copy-number vectors. A T7 promoter and a hepatitis delta virus ribozyme flank the genome. Sizes of each fragment are
shown. (B) H/PF/2013 virus isolate was harvested 4 days after infection of C6/36 cells at an MOI of 0.1. Recombinant virus was harvested 4 to 7 days after
electroporation of RNA into C6/36 cells. Titrations were performed in triplicate. (C) Virus focus images on Vero-81 cells. (D) Growth curves of H/PF/2013 natural
isolate and infectious clone at 32°C and 37°C. At both temperatures, the isolate grew significantly better than the infectious clone by 2-way analysis of variance.
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different temperatures to assess not only stability but also growth kinetics. The natural
isolate and clone virus have similar growth kinetics at 32°C and 37°C (Fig. 2D), indicating
that temperature had minimal impacts on the total amount of progeny virus that was
produced during infection. As seen with other ZIKV recombinant viruses (16), peak
infectious titers for the P1 stock of H/PF/2013 infectious clone (IC) were lower than
those for the natural isolate at both temperatures. The likely differences in isolate and
recombinant virus yields may reflect a loss in cooperativity due to the reduced
quasispecies populations present in the molecularly cloned stocks (28, 29).
Brazilian ZIKV strains. New ZIKV disease presentations, particularly microcephaly
and other birth defects, were first observed during the 2015-2016 ZIKV outbreak in
Brazil. In order to better assess the viral genetic determinants that may contribute to
these emerging phenotypes, we sought to develop an infectious clone of a contem-
porary outbreak strain from Brazil. However, as we were unable to access any virus
isolates from Brazil, we relied upon deposited sequences for clone construction. The
first Brazilian ZIKV sequence published online was strain SPH2015 (accession number
KU321639), which was isolated in March 2015 from a patient in São Paulo state (30) and
predates more commonly used Brazilian ZIKV strains such as the December 2015
PRVABC59 isolate. While the 5= UTR sequence of the SPH2015 strain was complete, the
final 129 nucleotides of the 3= UTR sequence were missing. Since we had no SPH2015
virus available for independent sequencing, we grafted the final 129 nucleotides from
H/PF/2013 (which is identical to PRVABC59) onto the SPH2015 sequence to produce a
complete ZIKV genome (Fig. 3A). The high nucleotide identity between H/PF/2013 and
these early Brazilian strains enabled us to use identical junctions to construct the
SPH2015 clone (and the BeH819015 clone [see below]), allowing easy production of
chimeric viruses by assembling different permutations of subgenomic fragments.
After repeated failed attempts at recovery, we compared the deposited SPH2015
sequence to more recently published sequences and identified a series of seven
nucleotides within the first 20 nt of the SPH2015 genome that did not match other ZIKV
strains, two of which (nt 10 and 15) were different from all other flaviviruses (Fig. 3A).
Using site-directed mutagenesis, we changed these seven nucleotides to match the
sequences of H/PF/2013 and PRVABC59 (which are identical in this region). This
modification allowed us to recover viable SPH2015 clone virus (Fig. 3C), suggesting that
the published sequence contains lethal errors and highlighting the usefulness of our
system in identifying and repairing such errors in the phylogenetic record.
Identification of two genetically distinct clades of ZIKV circulating in Brazil.
Phylogenetic analysis of available ZIKV sequences from the Brazilian outbreak revealed
the presence of two distinct clades of contemporary ZIKV strains (5); however, the
specific structure of the phylogenetic tree is sensitive to sequence variations. Because
the previously identified published 5= UTR sequence of SPH2015 resulted in lethal
variants, we excluded the 5= UTR from our phylogenetic analysis, providing additional
support for the existence of two independent clades of Brazilian strains (Fig. 4). The
smaller clade is composed of two Brazilian sequences clustering with the Haiti/1225/
2014 strain (Fig. 4), which preceded the first reports of ZIKV in Brazil. When the 5= UTR
sequences are included, the Haiti/1225/2014 clade is still a distinct monophyletic group;
however, the specific topology and node confidence within each clade are slightly
altered (Fig. S3). Irrespective of the phylogenetic approach (Fig. 4; Fig. S3), our infec-
tious clones represent one isolate from each clade. The French Polynesian strain
(H/PF/2013) acts as the closest relative to the Brazilian clades, consistent with previous
phylogenetic analyses published using a wider geographic range of isolates (31–34).
Our modified SPH2015 sequence falls into the smaller clade of Brazilian ZIKV. One of
the earliest and most complete sequences that we identified from the larger clade was
strain BeH819015 (accession number KU365778), which was isolated in Pará state in
July 2015 (5). The nucleotide sequence of BeH819015 is closest to but differs from the
ZIKV strains clustering with Haiti/1225/2014, from isolates from Oceania (such as
H/PF/2013), and from other isolates from the Caribbean (such as PRVABC59). To
demonstrate the tractability of our reverse genetics platform, we generated an infec-
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tious clone of ZIKV BeH819015 by using site-directed mutagenesis to change the six
nucleotide differences (five nonsynonymous changes and one nucleotide insertion in
the 5= UTR) in SPH2015 to those of BeH819015 (Fig. 3B). The BeH819015 recombinant
was viable and made infectious foci of similar size as the SPH2015 IC, but both are
smaller than H/PF/2013 and PR2015 (Fig. 3C; Fig. S2). Because we had no actual
Brazilian virus in the lab with which to compare our clones, we used the abovemen-
tioned PVRABC59 as a control for comparing the growth kinetics of our Brazilian
recombinant viruses in vitro. As shown in Fig. 3D, BeH819015 has a lower peak titer and
SPH2015 has slightly slower early growth; however, our synthesized Brazilian clones do
not have growth kinetics vastly altered from those of a commonly used natural isolate
strain. Taken together, these results demonstrate that we have reproduced a time-
ordered family of infectious ZIKV molecular clones and recombinant viruses that
precede and encompass the pandemic in the Western Hemisphere (Fig. 4, blue and red
boxes).
Antigenicity of ZIKV clones and cross-reactivity with DENV. We used a virus
capture enzyme-linked immunosorbent assay (ELISA) to measure binding of a panel of
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FIG 3 (A and B) Diagrams of ZIKV SPH2015 and BeH819015 infectious clones. (A) Diagram shows changes introduced into the first 20 nt to recover SPH2015
infectious clone virus. (B) Diagram of infectious clone BeH819015. Six nucleotide changes made to convert SPH2015 clone into BeH819015 are shown (red
arrows). (C) Virus focus images on Vero-81 cells. (D) Growth curves of PRVABC59 natural isolate and infectious clones of SPH2015 and BeH819015 at 37°C.
Although they differ by only 6 nucleotides, growth of SPH2015 was significantly different from that of BeH819015 by 2-way analysis of variance with Tukey’s
test.
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DENV monoclonal antibodies (MAbs) to the panel of isolate and recombinant ZIKVs,
compared to the four DENV serotypes. The MAb panel included four DENV serotype-
specific neutralizing MAbs (1F4, 2D22, 5J7, and 5H2) (Table S1). As expected, none of
these MAbs bound to any of the ZIKV strains tested (Fig. 5A). In contrast, MAbs 1C19
and 1M7, which bind the highly conserved fusion-loop region of all DENV serotypes
(Table S1), bound to all tested ZIKV strains (Fig. 5B). Dissimilarly, MAb 1B22, which binds
to prM on immature DENV virions, bound to all four DENV serotypes but none of the
ZIKV strains tested (Fig. 5B). To determine whether the lack of 1B22 binding to ZIKV was
due to the absence of prM present on ZIKV virions (35), or antigenic divergence
between DENV and ZIKV prM, we infected Vero-81 cells with DENV4 or ZIKV and stained
permeabilized cells. While anti-fusion loop MAb 4G2 stained all infected cells, anti-prM
DENV MAb 2H2 stained only DENV4-infected cells (Fig. S3), likely reflecting antigenic
divergence in prM between DENV and ZIKV. As there is extensive cross-reactivity
between antiflavivirus immune sera and ZIKV (36, 37), defining cross-reactive and
virus-specific epitopes between ZIKV and DENV is a critical component of developing
ZIKV diagnostics and understanding the mechanisms of ZIKV pathogenesis.
ZIKV infectious clones are virulent in a mouse model of lethal ZIKV disease.
Previous work has demonstrated that wild-type immunocompetent mice are resistant
to ZIKV pathogenesis but that mice lacking alpha/beta interferon (IFN-/) signaling
(e.g., Ifnar1/, A129, AG129, Irf3/  Irf5/  Irf7/) succumb to ZIKV infection
(38, 39). We infected 6- to 8-week-old Ifnar1/  Ifngr1/ (C57BL/6) mice with 102
to 103 FFU of ZIKV by a subcutaneous route and monitored weight loss and lethality
daily for 14 days (Fig. 6A to D). Mice were infected with the ZIKV H/PF/2013 isolate (n
9) or the H/PF/2013 infectious clone (n  9) or were mock infected with phosphate-
buffered saline (PBS) (n  7). Mice that received H/PF/2013 virus began to lose weight
at 5 days postinfection (Fig. 6A), while H/PF/2013 clone-infected mice exhibited more
gradual weight loss than those infected with the isolate virus (P  0.0001). All
ZIKV-infected mice succumbed to infection (Fig. 6B), but there was a statistical differ-
ence by log rank for recombinant viruses. Additional mice were infected with either of
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KU729217 - BeH823339 Brazil 2015
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KJ776791 - H/PF/2013 French Polynesia Com plete
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FIG 4 Phylogenetic tree of Brazilian ZIKV full-length sequences. ZIKV sequences were acquired from
GenBank and this study (see Materials and Methods), and the 5= UTR was removed from each lineage.
Multiple sequence alignment was performed using MAFFT, and the phylogenetic tree was generated
using maximum likelihood (RAxML software) with 100 bootstrap replicates. Only bootstrap support
values of 50 are displayed at each node. GenBank accession number and strain name are indicated on
each branch. Two distinct clades of Brazilian ZIKV sequences are highly supported (green box). SPH2015
and BeH819015 are boxed in blue and red, respectively.
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the Brazilian clones (SPH2015 IC or BeH819015 IC) with a higher dose of 103 FFU due
to unpublished data suggesting that these infectious clones are attenuated in com-
parison to the H/PF/2013 viruses in mice. SPH2015-infected mice started losing weight
by day 10 (Fig. 6C), signs of illness appeared by day 12, and all mice succumbed to
illness by day 18 (Fig. 6D). A statistical difference between the infected groups was seen
at days 17 and 18 by Bonferroni test (P  0.0184 and 0.009, respectively). Sixty-six
percent of BeH819015-infected mice showed no overt disease signs, leading to a
statistical difference in lethality when measured by a log-ranked Mantel test between
strains (Fig. 6D). In contrast, when we infected 6- to 8-week-old Ifnar1/mice with 105
FFU of ZIKV (clones SPH2015, H/PF/2013, and BeH819015), we observed no signs of
illness or weight loss over the course of 25 days (Fig. 6E). The increased morbidity and
mortality in Ifnar1/  Ifngr1/ mice compared to Ifnar1/ mice for all viruses
tested reveal a specific role for gamma interferon (IFN-) in controlling ZIKV
pathogenesis.
DISCUSSION
The emergence of ZIKV is the latest example of an Old World arbovirus spreading
rapidly upon arrival in the Americas, reminiscent of Chikungunya virus in 2013, West
Nile virus in 1999, multiple DENV serotypes in the 1980s, and, originally, the introduc-
tion of yellow fever virus in the 17th century. The emergence of ZIKV in the Americas
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FIG 5 Antibody binding to DENV and ZIKV clone viruses. (A) The highly DENV serotype-specific MAbs
1F4, 2D22, 5J7, and 5H2 clearly bind only the appropriate DENV serotype but not ZIKV. (B) The DENV
serotype-cross-reactive MAbs 1C19 and 1M7 bound all DENV and ZIKV strains tested, while 1B22, a
prM-specific MAb, bound only the 4 DENV serotypes. DT000 is serum isolated from a traveler with repeat
flavivirus vaccinations and infections and is used to control protein loading.
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and the concomitant association with congenital infection highlight the importance of
understanding the fundamental molecular mechanisms regulating flavivirus transmis-
sion, spread, and emergence. Here, we report the generation of a ZIKV reverse genetics
system, representing strains from both the African and Asian ZIKV lineages. We used
synthetic approaches to recover two recombinant viruses (SPH2015 and BeH819015)
representing early epidemic strains from two contemporary clades of ZIKV that are
circulating in Brazil. This panel of infectious clones also includes three allelic variants of
the prototype ZIKV strain (MR766). Additionally, we generated a clone of an isolate from
French Polynesia (H/PF/2013) that immediately preceded the current epidemic in the
Americas and is likely representative of the ZIKV strain that was introduced to Brazil.
Several groups have reported ZIKV clones using low-copy-number plasmids, plas-
mids with introns, or multipiece systems (15–17, 19) to overcome the bacterial toxicity
of the plasmids. Shan et al. derived a full-length infectious cDNA clone of a 2010 ZIKV
strain from Cambodia (FSS13025) using a sequentially assembled multipiece system to
generate a single-piece infectious clone (40). FSS13025 falls within the Asian lineage of
ZIKV strains but differs by approximately 19 amino acids from Latin American strains
such as SPH2015 and BeH819015. Other infectious clones of ZIKV strain Paraiba_01/
2015 (16) and MR766 (15) were propagated in a bacterial artificial chromosome as
complete genomes containing engineered introns and launched from DNA, not RNA.
Using our system, we generated a clone of the BeH819015 virus by introducing six
mutations to the SPH2015 background, which was straightforward because the
changes were distributed across the subgenomic fragments on four plasmids. In
contrast to other systems (16, 17), all of our subgenomic regions are maintained in
high-copy-number plasmids. Our quadripartite assembly scheme allows for flexible
construction of chimeric viruses, as contemporary strains share sufficient sequence
homology to use identical restriction sites, and so subgenomic fragments from different
strains can be interchanged. This allows rapid mapping of genetic determinants
between two virus strains. An overlapping quadripartite system was recently used to
FIG 6 In vivo pathogenesis studies. ZIKV H/PF/2013 isolate (n  9), infectious clone virus (n  9), or PBS (n  7) was inoculated into
IFNGR-knockout mice by footpad inoculation with 102 FFU (A and B). In parallel, Ifnar1/ and Ifngr1/mice were inoculated by footpad injection
with 103 FFU of BeH819015 (n  6) or SPH2015 (n  6) infectious clone or PBS (n  3) (C and D) or 105 FFU of recombinant SPH2015 (n  5),
BeH819015 (n 5), or H/PF/2013 (n 5) infectious clone (E), respectively. Weight loss and mortality were recorded through 25 days postinfection
or until all animals had succumbed to infection.
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construct a different MR766 strain incorporating green fluorescent protein (GFP) (19);
however, the stability of these reporter viruses was unclear given that GFP flaviviruses
are generally unstable (41).
Previous studies have analyzed ZIKV sequences from the current epidemic (5, 34, 42,
43), and two clades can be seen in some analyses; however, these reports have not
discussed the significance of the two distinct clades of Brazilian ZIKV isolates, as was
also found in our analysis (5, 34, 42, 43). The presence of two distinct clades could
indicate independent introductions of ZIKV into Brazil, an earlier introduction than
previously appreciated, novel evolutionary patterns, or errors in the published se-
quences. Additional factors to consider include geographic location, tissue source,
and/or disease presentation of the isolate viruses, although no relationship between
these factors and the clade separation was evident in the sequences considered in our
analysis. Better resolution of the tree topology and potential characteristics defining
each clade will be achieved as more isolates are sequenced and incorporated into
phylogenetic analyses. We generated infectious clones of two Brazilian ZIKV strains
representing each of the two identified clades, which will facilitate further analysis of
the properties that distinguish these two groups of epidemic ZIKV strains.
The ZIKV virus clones from both Brazilian clades (SPH2015 and BeH819015) are
antigenically similar to the Asian strain (H/PF/2013) and the African strain (MR766),
consistent with the idea that ZIKV strains circulate as a single serotype. DENV serotype-
specific antibodies do not bind any of the ZIKV isolates or clones, confirming the unique
antigenic areas of E protein between DENV and ZIKV. Conversely, all ZIKV strains are
recognized by cross-reactive DENV fusion-loop antibodies, affirming the homology of
ZIKV and DENV in this region. In contrast to the substantial antigenic cross-reactivity
between ZIKV and DENV E protein, a MAb that recognizes prM of all four DENV
serotypes did not bind to cells infected with any ZIKV strains, suggesting that prM is not
antigenically conserved. Currently, available ZIKV diagnostics are confounded by cross-
reactive binding to DENV in standard ELISAs (36, 37), so identifying antigenically
distinct epitopes is important for developing diagnostics that can identify ZIKV infec-
tion in DENV-seropositive individuals.
In Ifnar1/  Ifngr1/ mice, the H/PF/2013 isolate was significantly more virulent
than recombinant H/PF/2013, likely reflecting the reduced quasispecies complexity of
P0 recombinant virus stocks (16), a known virulence determinant (28, 29). Although the
BeH819015 and SPH2015 recombinant viruses differ by only six nucleotide changes
throughout their genomes, SPH2015 infection resulted in 100% mortality and earlier
morbidity than the less pathogenic BeH819015 strain. Importantly, all three recombi-
nant viruses were attenuated in Ifngr1/ mice, demonstrating the critical importance
of IFN- responses in controlling lethal ZIKV infections, as also reported by other groups
(38). It is interesting that the northern Brazil BeH819015 isolate was more strongly
associated with severe congenital disease than SPH2015 (5) but more attenuated in the
mouse model. Additional studies will be needed to identify the key residues respon-
sible for reduced BeH819015 pathogenesis in vivo.
After ZIKV infection, an unexpected development is the severe disease presenta-
tions, most significantly congenital infection and birth defects, associated with the
current ZIKV outbreak in Latin America and the Caribbean (44) and replicated in mouse
models of human disease (45, 46). An association between ZIKV infection and Guillain-
Barré syndrome was first noted during the 2013-2014 outbreak in French Polynesia (47),
and retrospective analyses of this outbreak identified previously unappreciated asso-
ciations with fetal neurodevelopmental abnormalities (48). More recently, ZIKV-
associated Guillain-Barré syndrome has been reported in the Americas as well (49, 50).
It is unclear why severe manifestations of ZIKV infection have become evident only in
the most recent outbreaks, and possible explanations include host genetic background,
host immune status, and the large size and intense surveillance of the current epidemic.
However, it is plausible that viral genetic changes could result in new disease pheno-
types. Previous analyses have speculated that this may be the case, based on sequence
comparisons of historic and contemporary ZIKV strains (42, 43). However, testing this
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hypothesis requires the ability to generate isogenic mutants to evaluate viral determi-
nants of pathogenesis. Our panel of ZIKV infectious clones representing historical and
contemporary virus strains, as well as the relative ease of generating allelic variants and
chimeric viruses using the quadripartite system, provides an essential toolkit for
determining the mechanisms of ZIKV pathogenesis and furthering the development of
new vaccines and antivirals.
MATERIALS AND METHODS
Cells and viruses. The MR766 strain of ZIKV was obtained from the World Reference Center for
Emerging Viruses and Arboviruses (R. Tesh, University of Texas Medical Branch). ZIKV strains H/PF/2013
and PRVABC59 were provided by the U.S. Centers for Disease Control and Prevention. Virus stocks were
prepared in C6/36 Aedes albopictus cells (ATCC catalog no. CRL-1660) or, where indicated, Vero-81
Cercopithecus aethiops cells (ATCC catalog no. CCL-81) and titrated in Vero-81 cells (51). C6/36 cells were
grown at 32°C with 5% CO2 in Eagle’s minimum essential medium (MEM) supplemented with 5%
heat-inactivated (HI) fetal bovine serum, nonessential amino acids, and antibiotics/antimycotics. Vero-81
cells were grown at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM)–F-12 50/50
medium (Gibco) supplemented with 5% HI fetal bovine serum and antibiotics/antimycotics (52). For
growth curve analyses, cells were infected at a multiplicity of infection (MOI) of 0.1 in triplicate, and
supernatants were collected at 4, 24, 48, 72, and 96 h postinfection and frozen at 80°C until titrated on
Vero-81 cells. Viral foci were detected at 44 to 48 h after infection, following fixation/permeabilization
with 4% paraformaldehyde-0.01% saponin using primary MAb E60 (38) or 4G2 (51) and secondary
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma), followed by TrueBlue substrate
(KPL). Number and size of foci were analyzed with a CTL Immunospot instrument.
Viral genome sequencing and modified 5=-3= RACE. Viral RNA was isolated using a QIAamp viral
RNA minikit (Qiagen), and cDNA libraries were prepared using Superscript III (Invitrogen). Sanger
sequencing was performed on PCR templates generated using Phusion High-Fidelity DNA polymerase
(New England BioLabs) and analyzed using Sequencher (Gene Codes) and Lasergene (DNAStar) software.
The 5= and 3= UTR sequences were determined as previously described (53). Briefly, viral RNA was
isolated and treated with calf intestinal phosphatase (Ambion) for 1 h at 37°C to remove terminal
phosphates of uncapped RNAs. Following a phenol-chloroform extraction and isopropanol precipitation,
the RNA was treated with tobacco acid pyrophosphatase (Ambion) for 1 h at 37°C. After another
phenol-chloroform extraction and isopropanol precipitation, the RNA was incubated with T4 RNA ligase
I (Ambion) for 1 h at 37°C and then overnight at 4°C, to ligate the 5= and 3= ends. cDNA (Superscript III;
Invitrogen) was made and used to generate an amplicon containing both the 5= and 3= UTR sequences,
which was Sanger sequenced.
ZIKV infectious clone design. We designed a quadripartite unidirectional molecular clone strategy
similar to that previously described for DENV and emerging coronaviruses (20–22, 24, 25). First, we
identified naturally occurring class IIG nonpalindromic restriction endonuclease sites within the six ZIKV
full-length genomes. For the clone of strain MR766, synonymous nucleotide changes were introduced at
positions 895, 901, 2983, 7834, 7837, 8467, and 8473 to eliminate four internal restriction enzyme sites
(two PflMI sites, an SmaI site, and a BstAPI site, respectively), simultaneously leaving marker mutations
for identifying recombinant viruses. A T7 promoter sequence was added to the immediate 5= end of the
genome, and a hepatitis delta virus ribozyme was added directly after the last nucleotide of each ZIKV
genome to generate an authentic 3= end. The four subgenomic fragments were synthesized into the
pUC57 vector (BioBasic) and amplified in Escherichia coli strain MC1061. The resulting purified plasmids
were digested, ligated, in vitro transcribed, and electroporated into C6/36 cells as previously described
(20–22). Supernatants from electroporated C6/36 cells were harvested after 6 to 7 days and passaged
once on C6/36 cells to generate virus stocks. Clone MR766 Del and MR766 Gly viruses were
generated by site-directed mutagenesis of the MR766 Gly clone. Except for the junction sites (Bsu36I,
BstXI, and SfiI), we used an identical strategy as for the H/PF/2013 clone and for SPH2015. Strain
BeH819015 was generated by site-directed mutagenesis of the SPH2015 clone in the six positions where
the two strains differed (5= UTR, T81ins; E, I384V; NS1, H951Y; NS3, Y1892H; NS4B, M2330I; and NS4B,
M2480I). We confirmed the sequence of all recombinant viruses.
Phylogenetic analysis. Full-length sequences (10,000 nt) were obtained from GenBank and from
sequencing of laboratory clones/isolates. Sequences were either manually edited to remove the 5= UTR,
left as downloaded, or manually modified to provide the viable 5= UTR sequence variants for Haiti/1225/
2014 and SPH2015. Multiple sequence alignments were performed using MAFFT (54). The best substi-
tution model for each alignment was evaluated using jModelTest (55) and identified to be a general
time-reversible (GTR) model with an estimated proportion of invariable sites and estimated gamma
shape parameter (GTR  I  G). Maximum likelihood phylogenetic trees were generated using RAxML
(56) using 100 bootstrap replicates. Trees were visualized using EvolView (57).
Virus capture ELISA. Virus particles were captured using mouse anti-DENV MAbs 4G2 and 2H2 in
carbonate buffer. MAbs (see Table S1 in the supplemental material) were diluted to a concentration of
20 ng/l and added to captured virus for 1 h at 37°C. After incubation with alkaline phosphatase-
conjugated secondary antibodies (Sigma), p-nitrophenylphosphate substrate (Sigma) was added and
absorbance at 405 nm was measured (Bio-Rad). Background signal (optical density at 405 nm [OD405]
with no primary antibody) was subtracted from each virus sample, and absorbance was normalized to
binding of an antiflavivirus human polyclonal serum sample.
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Animal studies. Animal husbandry and experiments were performed under the approval of the
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee. Six- to
8-week-old male and female Ifnar1/  Ifngr1/ mice on a C57BL/6 background were infected
subcutaneously via a footpad injection with 102 FFU of ZIKV H/PF/2013 isolate, infectious clone virus, or
PBS. In a separate study, mice were infected with 103 FFU of BeH819015 or SPH2015 infectious clones or
PBS. Mice were monitored daily for signs of morbidity or mortality and twice daily after losing 20% of
their starting weight. Animals that exhibited dual hind limb paralysis or loss of 30% of their starting
weight or that became moribund were humanely euthanized. Experiments were terminated 5 days
following the last signs of illness resolving. Six- to 8-week-old male and female Ifnar1/ mice (C57BL/6)
were infected with 105 FFU of ZIKV clones of SPH2015, BeH819015, or H/PF/2013. Mice were monitored
for 25 days with no adverse events noted.
SUPPLEMENTAL MATERIAL
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